|Drug Name:||Hydralazine Hydrocloride|
|Manufacturer:||AMERICAN REGENT, INC.|
Treatment: There is no specific antidote.Support of the cardiovascular system is of primary importance.
Shock should be treated with plasma expanders.
If possible, vasopressors should not be given, but if a vasopressor is required, care should be taken not to precipitate or aggravate cardiac arrhythmia.
Tachycardia responds to beta blockers.Digitalization may be necessary, and renal function should be monitored and supported as required.No experience has been reported with extracorporeal or peritoneal dialysis.
In a few patients hydralazine may produce a clinical picture simulating systemic lupus erythematosus including glomerulonephritis.
In such patients hydralazine should be discontinued unless the benefit-to-risk determination requires continued antihypertensive therapy with this drug.
Symptoms and signs usually regress when the drug is discontinued but residua have been detected many years later.
Long-term treatment with steroids may be necessary.(See PRECAUTIONS, Laboratory Tests.)